WuXi AppTec's Research Chemistry Services (RCS) is a global leading chemistry platform offering synthetic and medicinal chemistry solutions to pharmaceutical and biotech companies, as well as research institutes and non-profit foundations worldwide. As an integrated small molecule drug discovery platform, RCS provides both Full-time Equivalent (FTE) and Fee-for-Service (FFS) models, aimed at streamlining the drug discovery process, with emphasis on productivity, speed, flexibility, quality and reliability.
20 of global top 20 pharmaceutical companies
516 clients have FTE collaboration
27 clients with 50+ FTE team including: 13 clients with 100+ FTE teams
686 clients with >5 years' collaboration including: 162 clients with >10 years' collaboration
FFS collaboration covers 1,200+ customers from mg to kg scale synthesis
11,000+ Regular FFS Projects per year, > 95% on time delivery rate
2,000+ DPC (Discovery Process Chemistry) Projects per year
Consistently high customer satisfaction (Net Promoter Score >90)
WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations.
As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) from preclinical to commercial.
Integrated CMC platform for both API and drug product
9 development and manufacturing sites worldwide with one quality and EHS standard approved by all major regulatory agencies
Supported 50+ first-time new drugs approved in the US, Europe, China and Japan since 2017, 105 country approvals for branded drugs
Industry leading teams: 3,400+ process chemists & analytical scientists for API platform; 1,500+ formulation scientists & analytical scientists for drug product platform